Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insilico Medicine Partners with ASKA Pharma – AI‑Driven Target Discovery Collaboration Targets Gynecological Diseases

Fineline Cube Mar 24, 2026
Company Deals

Biocytogen Partners with Moonlight Bio – Antibody‑Cell Therapy Collaboration Targets Difficult‑to‑Treat Cancers

Fineline Cube Mar 24, 2026
Company Deals

Bio‑Thera Expands Intas Partnership to India – BAT2506 Golimumab Biosimilar Now Licensed Across US, Canada, and India

Fineline Cube Mar 24, 2026
Company Deals

Novartis Commits RMB 3.3 Billion China Investment – Expands Radioligand Therapy Ecosystem with Policy Push

Fineline Cube Mar 23, 2026
Company Deals

Everest Medicines Acquires Etripamil Rights from Corxel – USD 50 Million Deal for First‑in‑Class PSVT Nasal Spray in Greater China

Fineline Cube Mar 23, 2026
Policy / Regulatory

NHSA Unveils DRG 3.0 Grouping Scheme Roadmap – Systematic Upgrade Targets 2027 Implementation

Fineline Cube Mar 24, 2026
Company Drug

Qilu Pharma’s QLS1317 Wins NMPA Approval – First‑in‑Class MSI‑H Targeted Therapy Enters Solid Tumor Clinical Trials

Fineline Cube Mar 24, 2026
Company Drug

Innovent’s IBI302 Hits STAR Trial Primary Endpoint – Dual VEGF/Complement Inhibitor Shows 16‑Week Dosing and 50% Macular Atrophy Reduction in nAMD

Fineline Cube Mar 24, 2026
Company Deals

Convalife and Jointown Partner for Global Drug Development and Commercialization

Fineline Cube Oct 9, 2022

Shanghai-based Convalife Pharmaceuticals has entered into a strategic partnership with fellow Chinese firm Jointown Pharmaceutical...

Company Drug

Eli Lilly’s Retevmo Wins First China Approvals for RET-Driven Cancers

Fineline Cube Oct 9, 2022

Eli Lilly & Co (NYSE: LLY) has secured its first approvals in China for Retevmo...

Company Deals

VectorBuilder Raises $56.6M in Series C to Expand Life Science R&D

Fineline Cube Oct 9, 2022

Guangzhou-based VectorBuilder, a genetic engineering specialist incubated by the state-owned Guangzhou Industrial Investment and Capital...

Company Policy / Regulatory

WuXi Biologics Removed from US Unverified List Amid Ongoing Restrictions

Fineline Cube Oct 9, 2022

The US Commerce Department’s Bureau of Industry and Security (BIS) has updated its Unverified List...

Company Policy / Regulatory

India Launches Anti-Dumping Investigation Against Chinese Imports of Metronidazole

Fineline Cube Oct 9, 2022

The Union Ministry of Commerce and Industry in India has initiated an anti-dumping investigation into...

Policy / Regulatory

China’s NMPA Proposes Reforms to Enhance Radiopharmaceutical Review and Approval

Fineline Cube Oct 9, 2022

China’s National Medical Products Administration (NMPA) has released a draft proposal titled “Opinions on Reforming...

Company Drug

Ark Biosciences’ Ziresovir Shows Positive Results in Phase III AIRFLO Study for RSV Infection

Fineline Cube Oct 9, 2022

China-headquartered Ark Biosciences has announced positive results from the Phase III AIRFLO study for its...

Company Drug

Pfizer’s Talzenna Shows Positive Results in Phase III TALAPRO-2 Study for mCRPC

Fineline Cube Oct 9, 2022

US-based pharmaceutical giant Pfizer (NYSE: PFE) has announced positive results from the Phase III TALAPRO-2...

Company Drug

Hua Medicine’s Dorzagliatin Approved in China for Type 2 Diabetes

Fineline Cube Oct 9, 2022

China-based Hua Medicine (HKG: 2552) has announced that its Category 1 drug dorzagliatin has been...

Company Drug Medical Device

Allergan Aesthetics Launches Juvederm Volite in China’s Boao Lecheng

Fineline Cube Oct 9, 2022

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), has announced the commercial launch of Juvederm Volite...

Company Deals

Shanghai Lange Medtech Partners with Yantai Desheng for Fish-Derived Rotator Cuff Patch

Fineline Cube Oct 9, 2022

China-based Shanghai Lange Medtech Co., Ltd. has entered into a partnership with compatriot firm Yantai...

Company Deals

Roche Boosts China Investment with Additional RMB 250 Million

Fineline Cube Oct 9, 2022

Swiss pharmaceutical giant Roche (SWX: ROG) has pledged to invest an additional RMB 250 million...

Company Medical Device

Boston Scientific Launches Disposable RF Electrode for Chronic Pain in China

Fineline Cube Oct 8, 2022

Boston Scientific Corporation (NYSE: BSX), a US-based medical device company, has announced the official market...

Company Deals Digital R&D

Rundo Med-Tech Partners with Baidu to Advance Digital Clinical Trials

Fineline Cube Oct 8, 2022

Shanghai-based Contract Research Organization (CRO) Rundo Pharmaceutical R&D (Shanghai) Co., Ltd (Rundo Med-Tech) has entered...

Policy / Regulatory

China’s NMPA Releases 60th Batch of Reference Drugs for Generic Quality Evaluation

Fineline Cube Oct 8, 2022

The National Medical Products Administration (NMPA) has released the 60th batch of reference drugs for...

Company Deals

China Medical System Licenses Botulinum Toxin from South Korea’s BMI Korea

Fineline Cube Oct 8, 2022

China Medical System Holdings (CMS; HKG: 0867) has announced the establishment of a licensing agreement...

Company Drug

Junshi Biosciences Launches PD-1 Inhibitor Tuoyi for Advanced NSCLC in China

Fineline Cube Oct 8, 2022

Junshi Biosciences (HKG: 1877, SHA: 688180), a China-based biopharmaceutical company, has held a national market...

Company Deals

Betta Pharmaceuticals Raises $140.5M for Drug Industrialization Base in Zhejiang

Fineline Cube Oct 8, 2022

China’s Betta Pharmaceuticals Co., Ltd. (SHE: 300558) plans to raise RMB 1 billion ($140.5 million)...

Policy / Regulatory

China’s Volume-Based Procurement Cuts High-Value Medical Consumables Costs by 84%

Fineline Cube Oct 8, 2022

The national high-value medical consumables alliance procurement office has released the results of the third...

Company Drug

Everest Medicines’ Xerava Approved in Hong Kong for Complicated Intra-Abdominal Infections

Fineline Cube Oct 8, 2022

Everest Medicines Limited (HKG: 1952), a China-based biopharmaceutical company, has announced that it has received...

Posts pagination

1 … 590 591 592 … 638

Recent updates

  • Insilico Medicine Launches PandaClaw – AI Agent Platform Transforms Biological Research with Natural Language Interface
  • Insilico Medicine Partners with ASKA Pharma – AI‑Driven Target Discovery Collaboration Targets Gynecological Diseases
  • Qilu Pharma’s QLS1317 Wins NMPA Approval – First‑in‑Class MSI‑H Targeted Therapy Enters Solid Tumor Clinical Trials
  • NHSA Unveils DRG 3.0 Grouping Scheme Roadmap – Systematic Upgrade Targets 2027 Implementation
  • Biocytogen Partners with Moonlight Bio – Antibody‑Cell Therapy Collaboration Targets Difficult‑to‑Treat Cancers
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Insilico Medicine Launches PandaClaw – AI Agent Platform Transforms Biological Research with Natural Language Interface

Company Deals

Insilico Medicine Partners with ASKA Pharma – AI‑Driven Target Discovery Collaboration Targets Gynecological Diseases

Company Drug

Qilu Pharma’s QLS1317 Wins NMPA Approval – First‑in‑Class MSI‑H Targeted Therapy Enters Solid Tumor Clinical Trials

Policy / Regulatory

NHSA Unveils DRG 3.0 Grouping Scheme Roadmap – Systematic Upgrade Targets 2027 Implementation

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.